Stemline Therapeutics Announces FDA Acceptance of Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors

April 8, 2014 Stemline Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides engineered …